March 24, 2017 7:22 AM ET


Company Overview of Xencor, Inc.

Company Overview

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company’s product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukem...

111 West Lemon Avenue

Monrovia, CA 91016

United States

Founded in 1997

83 Employees



Key Executives for Xencor, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 46
Total Annual Compensation: $410.0K
Chief Medical Officer and Senior Vice President
Age: 62
Total Annual Compensation: $400.0K
Chief Scientific Officer and Senior Vice President of Research
Age: 52
Total Annual Compensation: $312.6K
Compensation as of Fiscal Year 2015.

Xencor, Inc. Key Developments

Xencor, Inc. Presents at Oppenheimer 27th Annual Healthcare Conference, Mar-22-2017 08:35 AM

Xencor, Inc. Presents at Oppenheimer 27th Annual Healthcare Conference, Mar-22-2017 08:35 AM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, New York, United States. Speakers: Bassil I. Dahiyat, Co-Founder, Chief Executive Officer, President and Director.

Bruce L.A. Carter Not to Stand for Re-Election as Chairman and Board Member of Xencor, Inc

Xencor Inc. announced that Bruce L.A. Carter, PhD will not stand for re-election to the board of directors at the 2017 Annual Meeting of Stockholders. Dr. Carter currently serves as the company's chairman as well as a member of the board of directors since 2009. In conjunction with the change, the company will continue its ongoing process to recruit additional board members with skill sets complementary to the current board.

Xencor, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016

Xencor, Inc. reported unaudited earnings results for the fourth quarter and full year ended December 31, 2016. For the quarter, the company reported net loss of $9,065,000 or $0.21 basic and dilutes per share compared to income of $7,757,000 or $0.19 basic and dilutes per share a year ago. Revenues were $6,440,000 against $21,754,000 a year ago. Loss from operations was $10,028,000 against income of $7,438,000 a year ago. Loss before income taxes was $9,225,000 compared to income before income taxes of $7,757,000 a year ago. For the year, the company reported net income of $23,625,000 or $0.56 dilute per share compared to $17,592,000 or $0.45 basic and dilute per share a year ago. Revenues were $87,520,000 against $27,762,000 a year ago. Income from operations was $22,540,000 against loss of $18,338,000 a year ago. Income before income taxes was $24,616,000 compared to loss before income taxes of $17,592,000 a year ago. Total revenues earned in 2016 were higher than 2015 due to revenue earned from Novartis Collaboration. The income earned for the year ended December 31, 2016 over the loss sustained in 2015 is primarily due to the revenue earned from Novartis collaboration.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Xencor, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at